Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janne Kaern

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2007
Adjuvant chemotherapy for early-stage ovarian cancer: review of the literatureClaes Tropé, Janne Kaern
Best Practice & Research. Clinical Obstetrics & Gynaecology|February 11, 2012
Borderline ovarian tumoursClaes Göran Tropé, Janne Kaern, Ben Davidson
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|November 18, 2003
[Paclitaxel should be included in standard therapy of ovarian carcinoma]Claes Tropé, Janne Kaern, Gunnar Saeter, et al.
Gynecologic Oncology|March 7, 2006
Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancerTorbjørn Paulsen, Janne Kaern, Kristina Kjaerheim, et al.
Cancer|February 22, 2002
Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosisChristian Marth, Jelena Kisic, Janne Kaern, et al.
Acta Obstetricia Et Gynecologica Scandinavica|May 24, 2018
Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum-sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry-based studyWitold Szczesny, Hilde Langseth, Tor Å Myklebust, et al.
Medical and Pediatric Oncology|February 12, 2002
Placental site trophoblastic tumor (PSTT) in mother and child: first report of PSTT in infancyTom Monclair, Vera M Abeler, Janne Kaern, et al.
Diagnostic Cytopathology|October 22, 2005
Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavitiesReuven Reich, Lina Vintman, Søren Nielsen, et al.
Journal of Cellular and Molecular Medicine|August 19, 2010
miRNA profiling along tumour progression in ovarian carcinomaOlga Vaksman, Helene Tuft Stavnes, Janne Kaern, et al.
International Journal of Oncology|April 27, 2013
Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patientsMouldy Sioud, Stein Saebøe-Larssen, Thea Eline Hetland, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2007
Adjuvant chemotherapy for early-stage ovarian cancer: review of the literatureClaes Tropé, Janne Kaern
Best Practice & Research. Clinical Obstetrics & Gynaecology|February 11, 2012
Borderline ovarian tumoursClaes Göran Tropé, Janne Kaern, Ben Davidson
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|November 18, 2003
[Paclitaxel should be included in standard therapy of ovarian carcinoma]Claes Tropé, Janne Kaern, Gunnar Saeter, et al.
Gynecologic Oncology|March 7, 2006
Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancerTorbjørn Paulsen, Janne Kaern, Kristina Kjaerheim, et al.
Cancer|February 22, 2002
Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosisChristian Marth, Jelena Kisic, Janne Kaern, et al.
Acta Obstetricia Et Gynecologica Scandinavica|May 24, 2018
Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum-sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry-based studyWitold Szczesny, Hilde Langseth, Tor Å Myklebust, et al.
Medical and Pediatric Oncology|February 12, 2002
Placental site trophoblastic tumor (PSTT) in mother and child: first report of PSTT in infancyTom Monclair, Vera M Abeler, Janne Kaern, et al.
Diagnostic Cytopathology|October 22, 2005
Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavitiesReuven Reich, Lina Vintman, Søren Nielsen, et al.
Journal of Cellular and Molecular Medicine|August 19, 2010
miRNA profiling along tumour progression in ovarian carcinomaOlga Vaksman, Helene Tuft Stavnes, Janne Kaern, et al.
International Journal of Oncology|April 27, 2013
Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patientsMouldy Sioud, Stein Saebøe-Larssen, Thea Eline Hetland, et al.
Pageof 2